Pathological blood lipid and apolipoprotein alterations following long-term anabolic androgenic steroid (AAS) use

F.M. Grace, N. Sculthorpe, M. Graham, J.S. Baker, M. Edwards, B. Davies

Research output: Contribution to journalMeeting Abstractpeer-review


With the huge market potential for testosterone therapy, information regarding the long-term health effects of AAS administration is of paramount importance.

The present study addresses the effects of such prolonged administration of supraphysiological AAS doses on cholesterol subfractions and apolipoproteins.

Subjects were divided into four distinct groups; (A) AAS users (n 8) who were still using at time of testing; (B) AAS users (n 8) who had been abstinent for a period greater than three months (mean SD: 5 2.3 months), (C) bodybuilding controls
(n 8) who did not use any pharmacological ergogenic aids, and (D) sedentary male controls (n 8). AAS use was confirmed through the measurement of Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Sex Hormone Binding Globulin. Data was analysed using the SPSS version 10.0 for Windows statistics package using appropriate statistics.
HDL, Apo-AI and Apo-AII were significantly lower, whereas LDL and Apo-B were significantly higher in the AAS-On group, compared with the non-AAS using groups. 
This level of HDL depression is consistent with many previous reports assessing HDL-C in bodybuilders self-administering AAS. Although definitive mechanisms are unknown, the enzyme Hepatic Triglyceride Lipase is thought to play an important role in the catabolism of HDL. However, the lack of a significant
difference between both groups of AAS users for both Apo-AI and Apo-AII suggests that androgen induced decrements may be more prolonged following the long-term administration of these drugs.
Original languageEnglish
Pages (from-to)615-615
Number of pages1
JournalAnnals of Nutrition and Metabolism
Publication statusPublished - 2003
Externally publishedYes


Dive into the research topics of 'Pathological blood lipid and apolipoprotein alterations following long-term anabolic androgenic steroid (AAS) use'. Together they form a unique fingerprint.

Cite this